Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Eosinophilic Esophagitis | 7 | 2019 | 22 | 3.050 |
Why?
|
| Gastroesophageal Reflux | 8 | 2017 | 129 | 1.580 |
Why?
|
| Proton Pump Inhibitors | 5 | 2019 | 34 | 1.210 |
Why?
|
| Deglutition Disorders | 5 | 2024 | 126 | 1.120 |
Why?
|
| Peptic Ulcer | 2 | 2019 | 18 | 1.120 |
Why?
|
| Esophageal Achalasia | 4 | 2020 | 61 | 0.940 |
Why?
|
| Esophageal Sphincter, Lower | 4 | 2024 | 32 | 0.930 |
Why?
|
| Monitoring, Ambulatory | 2 | 2016 | 32 | 0.860 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2024 | 16 | 0.840 |
Why?
|
| Esophageal pH Monitoring | 5 | 2016 | 14 | 0.760 |
Why?
|
| Budesonide | 2 | 2019 | 46 | 0.720 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 882 | 0.710 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2024 | 244 | 0.700 |
Why?
|
| Esophagoscopy | 3 | 2018 | 91 | 0.680 |
Why?
|
| Esophagus | 4 | 2016 | 108 | 0.660 |
Why?
|
| Dilatation | 3 | 2016 | 46 | 0.650 |
Why?
|
| Helicobacter Infections | 2 | 2019 | 36 | 0.640 |
Why?
|
| Helicobacter pylori | 2 | 2019 | 36 | 0.640 |
Why?
|
| Esophagitis | 2 | 2016 | 40 | 0.580 |
Why?
|
| Manometry | 5 | 2024 | 43 | 0.550 |
Why?
|
| Esophageal Stenosis | 2 | 2015 | 25 | 0.540 |
Why?
|
| Anti-Ulcer Agents | 1 | 2018 | 22 | 0.540 |
Why?
|
| Laryngopharyngeal Reflux | 1 | 2017 | 2 | 0.530 |
Why?
|
| Malus | 1 | 2017 | 2 | 0.530 |
Why?
|
| Weight Loss | 2 | 2016 | 245 | 0.490 |
Why?
|
| Esophageal Mucosa | 1 | 2016 | 4 | 0.490 |
Why?
|
| Cough | 2 | 2016 | 61 | 0.480 |
Why?
|
| Telemetry | 1 | 2016 | 30 | 0.480 |
Why?
|
| Mediastinal Diseases | 1 | 2016 | 21 | 0.480 |
Why?
|
| Granuloma | 1 | 2016 | 65 | 0.470 |
Why?
|
| Consensus | 1 | 2017 | 315 | 0.460 |
Why?
|
| Enteropathy-Associated T-Cell Lymphoma | 1 | 2015 | 2 | 0.450 |
Why?
|
| Intestinal Neoplasms | 1 | 2015 | 77 | 0.420 |
Why?
|
| Diarrhea | 1 | 2015 | 180 | 0.410 |
Why?
|
| Esophageal Motility Disorders | 2 | 2024 | 17 | 0.410 |
Why?
|
| Fluticasone | 4 | 2019 | 31 | 0.390 |
Why?
|
| Decision Trees | 1 | 2012 | 63 | 0.370 |
Why?
|
| Humans | 33 | 2024 | 98080 | 0.360 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 155 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1110 | 0.340 |
Why?
|
| Endoscopy, Digestive System | 3 | 2016 | 73 | 0.300 |
Why?
|
| Fundoplication | 4 | 2017 | 78 | 0.290 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2008 | 10 | 0.280 |
Why?
|
| Hyperammonemia | 1 | 2008 | 14 | 0.280 |
Why?
|
| Steroids | 2 | 2019 | 168 | 0.270 |
Why?
|
| Brain Edema | 1 | 2008 | 55 | 0.270 |
Why?
|
| Liver Cirrhosis | 1 | 2008 | 288 | 0.240 |
Why?
|
| Adult | 15 | 2024 | 29539 | 0.230 |
Why?
|
| Gastrointestinal Agents | 2 | 2018 | 197 | 0.230 |
Why?
|
| Electric Impedance | 3 | 2016 | 118 | 0.230 |
Why?
|
| Pharmacogenetics | 2 | 2019 | 472 | 0.220 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 218 | 0.220 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2024 | 10 | 0.210 |
Why?
|
| Glucocorticoids | 2 | 2018 | 370 | 0.210 |
Why?
|
| Single-Blind Method | 2 | 2015 | 162 | 0.200 |
Why?
|
| Cannabis | 1 | 2024 | 41 | 0.200 |
Why?
|
| Prospective Studies | 5 | 2016 | 4823 | 0.190 |
Why?
|
| Diabetes Complications | 1 | 2024 | 176 | 0.190 |
Why?
|
| Male | 17 | 2024 | 47076 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 1782 | 0.170 |
Why?
|
| Female | 17 | 2024 | 51536 | 0.170 |
Why?
|
| Disease Management | 2 | 2020 | 377 | 0.160 |
Why?
|
| Peristalsis | 1 | 2020 | 10 | 0.160 |
Why?
|
| Hospitalization | 2 | 2020 | 991 | 0.160 |
Why?
|
| Middle Aged | 14 | 2024 | 29428 | 0.160 |
Why?
|
| Treatment Outcome | 7 | 2018 | 9711 | 0.150 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2006 | 677 | 0.150 |
Why?
|
| Colonoscopy | 2 | 2015 | 306 | 0.150 |
Why?
|
| Colectomy | 1 | 2020 | 201 | 0.140 |
Why?
|
| Interleukin-13 | 1 | 2019 | 42 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 139 | 0.140 |
Why?
|
| Prescription Drugs | 1 | 2019 | 42 | 0.140 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2784 | 0.140 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2016 | 488 | 0.140 |
Why?
|
| Proton Pumps | 1 | 2017 | 6 | 0.130 |
Why?
|
| Americas | 1 | 2017 | 21 | 0.130 |
Why?
|
| Hypopharynx | 1 | 2017 | 9 | 0.130 |
Why?
|
| Diet, Mediterranean | 1 | 2017 | 6 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 1103 | 0.130 |
Why?
|
| Laparoscopy | 4 | 2017 | 791 | 0.130 |
Why?
|
| Asia | 1 | 2017 | 109 | 0.130 |
Why?
|
| Barrett Esophagus | 1 | 2018 | 94 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 158 | 0.130 |
Why?
|
| Climate | 1 | 2017 | 63 | 0.130 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 1284 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 255 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 2013 | 0.120 |
Why?
|
| Attitude to Health | 1 | 2018 | 217 | 0.120 |
Why?
|
| Europe | 1 | 2017 | 356 | 0.120 |
Why?
|
| Hoarseness | 1 | 2016 | 12 | 0.120 |
Why?
|
| Transducers | 1 | 2016 | 37 | 0.120 |
Why?
|
| Itraconazole | 1 | 2016 | 13 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 305 | 0.120 |
Why?
|
| Food, Formulated | 1 | 2016 | 25 | 0.120 |
Why?
|
| Respiratory Sounds | 1 | 2016 | 40 | 0.120 |
Why?
|
| Biological Products | 1 | 2019 | 189 | 0.120 |
Why?
|
| Aged | 8 | 2024 | 21758 | 0.120 |
Why?
|
| Urban Population | 1 | 2017 | 246 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2017 | 166 | 0.120 |
Why?
|
| Mucous Membrane | 2 | 2014 | 82 | 0.120 |
Why?
|
| Dexlansoprazole | 1 | 2015 | 1 | 0.120 |
Why?
|
| Catheters | 1 | 2016 | 109 | 0.110 |
Why?
|
| Esophagoplasty | 1 | 2015 | 9 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2016 | 126 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2018 | 353 | 0.110 |
Why?
|
| Food Hypersensitivity | 1 | 2016 | 90 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 314 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 1567 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 305 | 0.100 |
Why?
|
| Sex Factors | 1 | 2017 | 1138 | 0.100 |
Why?
|
| Genome, Human | 1 | 2019 | 832 | 0.100 |
Why?
|
| Crohn Disease | 1 | 2020 | 844 | 0.100 |
Why?
|
| Hernia, Hiatal | 1 | 2013 | 38 | 0.090 |
Why?
|
| Tennessee | 1 | 2012 | 18 | 0.090 |
Why?
|
| Age Factors | 1 | 2017 | 1962 | 0.090 |
Why?
|
| Oliguria | 1 | 2012 | 6 | 0.090 |
Why?
|
| Acoustics | 1 | 2012 | 48 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1416 | 0.090 |
Why?
|
| Patient Selection | 1 | 2016 | 726 | 0.090 |
Why?
|
| Metered Dose Inhalers | 1 | 2012 | 33 | 0.090 |
Why?
|
| Urinary Bladder Diseases | 1 | 2012 | 40 | 0.090 |
Why?
|
| Androstadienes | 1 | 2012 | 71 | 0.090 |
Why?
|
| Ascites | 1 | 2012 | 55 | 0.090 |
Why?
|
| Creatinine | 1 | 2012 | 313 | 0.080 |
Why?
|
| Biopsy | 1 | 2015 | 1224 | 0.080 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2012 | 163 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1815 | 0.080 |
Why?
|
| Self Report | 1 | 2012 | 355 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 1211 | 0.080 |
Why?
|
| Urinary Bladder | 1 | 2012 | 261 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 358 | 0.080 |
Why?
|
| Young Adult | 3 | 2020 | 7507 | 0.080 |
Why?
|
| Logistic Models | 1 | 2012 | 1275 | 0.070 |
Why?
|
| Research Design | 1 | 2012 | 660 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2024 | 10973 | 0.070 |
Why?
|
| Disease Progression | 2 | 2018 | 1610 | 0.070 |
Why?
|
| Pharmacogenomic Testing | 2 | 2019 | 119 | 0.070 |
Why?
|
| Risk Factors | 3 | 2020 | 6233 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 2037 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1764 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2006 | 218 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2666 | 0.050 |
Why?
|
| Diabetic Neuropathies | 1 | 2024 | 43 | 0.050 |
Why?
|
| Biomarkers | 2 | 2012 | 2020 | 0.050 |
Why?
|
| Precision Medicine | 2 | 2019 | 503 | 0.050 |
Why?
|
| Dronabinol | 1 | 2024 | 60 | 0.050 |
Why?
|
| Recurrence | 2 | 2016 | 1254 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 3022 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 4025 | 0.040 |
Why?
|
| Esomeprazole | 1 | 2018 | 2 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 7389 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 903 | 0.030 |
Why?
|
| Prednisone | 1 | 2018 | 251 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 169 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 922 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 155 | 0.030 |
Why?
|
| Research | 1 | 2019 | 257 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 3212 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 811 | 0.030 |
Why?
|
| Perception | 1 | 2018 | 187 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2016 | 47 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 754 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 113 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 257 | 0.030 |
Why?
|
| Adolescent | 2 | 2020 | 10080 | 0.030 |
Why?
|
| Sleep | 1 | 2020 | 465 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 455 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 146 | 0.030 |
Why?
|
| Illinois | 1 | 2016 | 522 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1012 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 580 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 320 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2016 | 850 | 0.020 |
Why?
|
| Rupture | 1 | 2012 | 59 | 0.020 |
Why?
|
| Prognosis | 1 | 2020 | 4116 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 1099 | 0.020 |
Why?
|
| Infant | 1 | 2018 | 3328 | 0.020 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2012 | 119 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2018 | 4001 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2585 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 301 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7681 | 0.020 |
Why?
|